Next Phase Newsletter

An investment firm and incubator headquartered in the US has about $100M in assets under management, and the firm prefers to participate in early-stage and seed (pre-Series A) financing as well as later-stage and pre-IPO (post-Series B and C) financing while avoiding the middle-stages. The firm manages an Evergreen fund with between $10M-20M of available capital per year. The firm typically makes around 3 or 4 investments per year with typical initial allocation size between $2M-5M for early-stage companies and around $10M for later-stage companies. The firm utilizes various capital structures as determined on a case- by-case basis and has experience with equity investments and convertible loans. The firm primarily invests in companies based in the United States and China but is open to considering all global opportunities as well.

The firm is primarily interested in investing in companies in the biotechnology therapeutics and medical technology sectors. The firm will consider all modalities across these sectors but has expertise in molecule development and prefers to avoid medical devices. The firm has no experience in digital health but will consider investments in the diagnostics sector but prefers to focus on genomics and biomarker diagnostics. The firm will invest in therapeutics that are pre-clinical or in Phase I to Phase III of clinical trials as well as medical technology and diagnostics that are in development or clinical. The firm is disease agnostic and will consider companies across all indications but has experience investing in cancer and autoimmune related technologies.

The firm prefers to work with experienced management teams are dedicated to their technology and their company. The firm is an active investor and will take a board seat on a case-by-case basis depending on investment size. The firm will act as both a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global investor, headquartered in Western Europe with no geographical restrictions, is actively seeking new investment opportunities. The firm is a specialist biotech investor with an exclusive focus on therapeutics for oncology and genetic diseases. The firm makes selective investments in newly founded or early-stage companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. Typically, the firm invests in incorporated companies from seed stage onwards, and it can invest $25-30M over the lifetime of the companies. Currently, the firm is raising its fourth fund which in addition to its core strategy to invest in early stage companies, will also be used to invest in late stage financings, cross-over financings, IPO’s, and listed stock. These companies can either be portfolio companies or external companies.

In the life sciences, the firm is currently seeking new investments targeting the development of oncology therapies and therapeutics targeting genetic diseases, and is open to all types of therapeutic modalities and all indications relevant to those spaces, including platform technologies. The firm will typically not invest in medical devices or diagnostics, unless as companion to a therapeutic solution. Projects will be evaluated on solid preclinical proof-of-concept (late preclinical stage/pre-IND or early clinical), and will often fund the companies at least up to human proof-of-concept (clinical Phase Ib – Phase IIa).

At its core, the firm only invests in private companies with experienced management teams and breakthrough potential. The firm most often takes the responsibility to be lead investor, alone or in syndicate as the opportunity demands, and wants to be actively involved in the successful development and growth of its portfolio companies. To this end, the firm has several experts in oncology and genetic diseases, intellectual property, and drug development on the investment team which are available to the portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Singapore, with an additional office in the US makes early up to expansion stage investments across several industries including healthcare. The investment size is highly variable depending on the stage of the company. The firm invests in companies in North America and Europe that has a market expansion strategy in Asia and/or Singapore. The firm is actively seeking new investment opportunities.

In the Life Sciences, the firm is currently seeking medical devices, synthetic biology and digital health. For medical devices, the firm is opportunistic in terms of subsectors and indications. The firm looks for devices that are ready for commercialization. The firm is currently not looking for drug development companies.

The firm seeks entrepreneurs who are passionate, driven and enthusiastic, with sustainable business models and ideas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

With multiple offices throughout the US, a new business unit within a large corporation is focused on improving the quality, affordability and equity of employer-sponsored health care. This new investment arm is investing from the corporate’s balance sheet in early-stage and advanced health companies that offer accountable care and value-based solutions to employers and employees.

The firm’s “sweet spot” is in Series B and beyond. While the organization primarily deploys growth equity capital, it can consider making investments into earlier stage companies. The firm can invest in, and will consider opportunities outside of the U.S. market, but these opportunities must be focused on the employer-sponsored insurance market in the U.S.

Within healthcare, the firm invests primarily in accountable care-centered solutions and integrated disease management programs. The firm’s core focus areas are care delivery, priority conditions, analytics & enablers of advanced medical care, and pharma services.

The firm is also focused on health solutions that can be implemented in a remote or at-home setting, reducing the burden of patients. In terms of stage of development, the firm expects to see customer traction and revenue generation taking place – companies who are still developing a working product that has yet to be implemented will generally be considered too early for investment.

The firm seeks to invest in companies that have established substantial validation on their product/technology. The firm has board representation with each of the companies it has invested in and has typically served as a syndicate partner to lead investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A women-led venture capital is raising a new venture fund and is looking to invest in life science companies that address women’s health between Seed to Series A in Europe, the UK, and Israel, eventually scaling to the U.S as well. Typical check sizes range anywhere between £500k-1M for the first round and will double down up to £2M in Series A. The firm is open to acting as a lead investor for smaller rounds, however they are currently co-investing especially as they start to invest in the U.S.

The firm is open to any life science sector including therapeutics, diagnostics, medical devices, digital health, etc. in the clinical stage as long as the company addresses women’s health. This includes innovations that solely, disproportionately, and/or differently affect women, such as menopause, autoimmune diseases, and heart disease. The firm is open to anywhere from therapeutics and genomics to consumer products. The firm requires to see clinical data and efficacy in the technology. In terms of medical devices, the firm is open to all classes. The only exception that the firm does not invest in is pharmaceuticals.

The firm does not have specific team requirements, however the firm will take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A multibillion corporation headquartered in Saudi Arabia has a venture arm that invests in healthcare. The firm started as an end-to-end logistics and commercialization partner for healthcare products (including pharmaceuticals and medical devices) mainly for global blue chips, with manufacturing facilities in partnership with large corporations. The corporation’s venture arm will be contributing to investments in biotech companies in Series A and later stage companies.

Initial investments will range from $3M-5M in the form of a combination of equity and cash or non-diluted equity if the company has assets that could be leveraged in Saudi Arabia, which includes performing clinical research, manufacturing, and/or commercialization. The firm is predominantly interested in innovative therapeutics, digital health, and personalized diagnostics  and with a preference for companies prioritizing US FDA and/or EMA approval. For therapeutics, the firm prefers clinical stage companies. For digital health and diagnostics, the firm prefers companies that have beta tested their product/platforms.

Within therapeutics, the firm is focused on cell and gene therapy in Phase 2 and/or moving into Phase 3, with expectations for accelerated approvals. There are several indications of interest, including rare diseases, oncology, neurodegeneration, immunology, metabolic diseases, therapeutic vaccines, and regenerative therapeutics. Within digital health and diagnostics, the firm is primarily interested in technologies that are enterprise solutions, provider prescribed, personalized medicine or drug discovery engines.

The firm is only interested in companies willing to work with Saudi Arabia toward the goal of bringing biotech innovation to the Gulf and Middle Eastern regions. Relocation is not required, however, a carveout or partnership at least in Saudi Arabia and other Gulf countries is necessary. The firm does not require a board seat but does prefer an observer seat after equity investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in Japan manages a fund dedicated specifically to life science investments. Though it could largely vary on a deal-by-deal basis, the firm’s initial size of investment is usually around $1M, with a significant portion dedicated to follow-on investments. Geographically, the firm is focused on companies headquartered in Japan and those that are looking to expand into the Japanese market.

The firm is most interested in biotech and digital health technologies. The firm is very interested in emerging therapeutic technologies such as cell and gene therapy, as well as platform technologies. With regards to digital health technologies, the firm is most interested in (i) IT solutions for people in terms of health management, disease prevention, diagnosis, therapy, disease management, and nursing care; (ii) healthcare industry in terms of drug discovery & development, medical information, distribution system by leveraging AI, big data, IoT, VR, etc. The firm is opportunistic in terms of stage, and will seek opportunities that are pre-clinical and beyond.

The firm is actively seeking opportunities in Japan and those that are looking to expand into Japan. The firm will prefer to lead investments in companies headquartered in Japan where they can best leverage their resources and network, but will generally follow larger syndicates for deals outside of Japan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.